Patents by Inventor Bhuvanesh Singh

Bhuvanesh Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250120965
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 5, 2024
    Publication date: April 17, 2025
    Inventors: Jaeki MIN, Daniel C. SCOTT, Deepak BHASIN, Brenda A. SCHULMAN, Bhuvanesh SINGH, Jared T. HAMMILL, R. Kiplin GUY
  • Patent number: 11963954
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: April 23, 2024
    Assignees: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
    Inventors: Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
  • Publication number: 20230021224
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: September 9, 2021
    Publication date: January 19, 2023
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Jaeki MIN, Daniel C. SCOTT, Deepak BHASIN, Brenda A. SCHULMAN, Bhuvanesh SINGH, Jared T. HAMMILL, R. Kiplin GUY
  • Publication number: 20220280488
    Abstract: A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 22, 2020
    Publication date: September 8, 2022
    Applicants: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, MEMORIAL SLOAN-KETTERING CANCER CENTER, St. Jude Children's Research Hospital, Inc.
    Inventors: Hoshin KIM, Rodney Kiplin GUY, Jared T. HAMMILL, Daniel Charles SCOTT, Benda Arlene SCHULMAN, Bhuvanesh SINGH
  • Patent number: 11116757
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: September 14, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
  • Publication number: 20210069172
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 13, 2019
    Publication date: March 11, 2021
    Applicants: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
    Inventors: Jaeki MIN, Daniel C. SCOTT, Deepak BHASIN, Brenda A. SCHULMAN, Bhuvanesh SINGH, Jared T. HAMMILL, R. Kiplin GUY
  • Patent number: 10525048
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 7, 2020
    Assignees: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
    Inventors: Jaeki Min, Daniel C. Scott, Deepak Bhasin, Brenda A. Schulman, Bhuvanesh Singh, Jared T. Hammill, R. Kiplin Guy
  • Publication number: 20180256558
    Abstract: In one aspect, the invention relates to substituted 1-phenyl-3-(piperidin-4-yl)urea analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the DCN1-UBC12 interaction inhibitors of DCN1-mediated cullin-RING ligase activity, methods of making same, pharmaceutical compositions comprising same, methods of treating disorders using the disclosed compounds and compositions, methods of treating disorders associated with a DCN1-UBC12 interaction dysfunction, methods of treating disorders associated with a DCN1-mediated cullin-RING ligase activity dysfunction, methods of male contraception comprising the disclosed compounds and compositions, and kits comprising the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: September 19, 2016
    Publication date: September 13, 2018
    Applicants: Memorial Sloan Kettering Cancer Center, St. Jude Children's Research Hospital
    Inventors: Jaeki MIN, Daniel C. SCOTT, Deepak BHASIN, Brenda A. SCHULMAN, Bhuvanesh SINGH, Jared T. HAMMILL, R. Kiplin GUY
  • Patent number: 8530437
    Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: September 10, 2013
    Assignees: Sloan Kettering Institute for Cancer Research, Virttu Biologics Limited
    Inventors: Susanne Moira Brown, Paul Dunn, Bhuvanesh Singh, Ian Ganly
  • Publication number: 20090274728
    Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.
    Type: Application
    Filed: May 6, 2009
    Publication date: November 5, 2009
    Applicants: CRUSADE LABORATORIES LIMITED, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Susanne Moira Brown, Bhuvanesh Singh, Ian Ganly, Paul Dunn
  • Patent number: 7348418
    Abstract: Novel nucleic acids and polypeptides encoded thereby are provided that are highly duplicated and overexpressed in squamous cell carcinomas of a variety of tissues. Antibodies specific for binding the novel polypeptides are also provided. The invention further discloses several assays for gene duplication and overexpression of the novel gene and excessive production of the novel polypeptide in a sample. These assays permit assessing copy number in a sample from a subject, and contribute to the diagnosis, prognosis and development of therapeutic strategy for a pathology such as squamous cell carcinoma in a subject.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: March 25, 2008
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Bhuvanesh Singh, Pabbathi Thirumal Reddy, legal representative, Pabbathi Gopal Reddy
  • Publication number: 20070003520
    Abstract: An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.
    Type: Application
    Filed: November 17, 2004
    Publication date: January 4, 2007
    Inventors: Susanne Brown, Bhuvanesh Singh, Ian Ganly, Paul Dunn
  • Publication number: 20040009541
    Abstract: Novel nucleic acids and polypeptides encoded thereby are provided that are highly duplicated and overexpressed in squamous cell carcinomas of a variety of tissues. Antibodies specific for binding the novel polypeptides are also provided. The invention further discloses several assays for gene duplication and overexpression of the novel gene and excessive production of the novel polypeptide in a sample. These assays permit assessing copy number in a sample from a subject, and contribute to the diagnosis, prognosis and development of therapeutic strategy for a pathology such as squamous cell carcinoma in a subject.
    Type: Application
    Filed: February 10, 2003
    Publication date: January 15, 2004
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Bhuvanesh Singh, Pabbathi Gopal Reddy, Pabbathi Thirumal Reddy